

Submission No. : IS07-0001

Session Title : Industry Symposium 7

Session Topic : SK chemicals

Date & Time, Place : June 14 (Fri) / 12:00-13:00 / Room 4 (201)

---

## **Nafamostat as an Anticoagulant on CRRT**

**Jung Nam An**

*Hallym University Sacred Heart Hospital, Republic of Korea*

---

**\*\* Nafamostat Mesilate (NM) \*\*** 1. Serine Protease Inhibitor; Short acting & Dialyzable 2. Decrease in anticoagulation activity by the dilution in venous circuit and intracorporeal circulation \ Good candidate for regional anti-coagulant : Particularly for extracorporeal circulation (ECC; hemodialysis or plasmapheresis) in patients with bleeding complications or bleeding tendencies : Multi-inhibitory effects on the activated pathway by ECC; safer anticoagulant for many blood purification materials 3. Initiate washing/filling of blood route using 20 mg of Nafamostat dissolved in 500 ml of saline. : Inject continuously at 20-50 mg/hr as Nafamostat dissolved in 5% glucose solution into the anticoagulant injection line. 4. Nafamostat mesilate lengthens the filter life span with similar side effects to heparin or no anticoagulation in CKRT. : The use of NM was associated with decreased incidence of bleeding complications compared with the use of UFH. : NM is a safe and effective anticoagulant for CKRT in critically ill AKI patients with bleeding tendencies. 5. There are no meaningful difference in filter lifespan between the original and generic versions of nafamostat mesylate. : However, TMP was lower in the original product group than in the generic product group.

**Keywords:** Nafamostat Mesilate, Short acting, Dialyzable, Regional anti-coagulant, AKI patients with bleeding tendencies